BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 171 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,702 | +58.8% | 100,000 | 0.0% | 0.01% | +50.0% |
| Q2 2023 | $1,702 | -0.3% | 100,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,707 | +357.6% | 100,000 | +100.0% | 0.00% | +300.0% |
| Q4 2022 | $373 | -99.9% | 50,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $500,000 | +45.3% | 50,000 | +25.6% | 0.00% | 0.0% |
| Q2 2022 | $344,000 | -16.7% | 39,800 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $413,000 | -20.1% | 39,800 | +9.9% | 0.00% | 0.0% |
| Q4 2021 | $517,000 | -68.6% | 36,200 | +2.8% | 0.00% | -80.0% |
| Q3 2021 | $1,648,000 | -47.3% | 35,200 | -33.8% | 0.01% | -44.4% |
| Q2 2021 | $3,130,000 | +1.3% | 53,200 | 0.0% | 0.01% | -10.0% |
| Q1 2021 | $3,089,000 | +21.4% | 53,200 | +39.3% | 0.01% | 0.0% |
| Q4 2020 | $2,545,000 | +75.5% | 38,200 | -4.7% | 0.01% | +66.7% |
| Q3 2020 | $1,450,000 | – | 40,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |